Allergan Bolsters Blockbuster Botox With Topical Toxin Buy
This article was originally published in Scrip
Executive Summary
Allergan PLC will pay $90m up front to acquire the topical botulinum toxin maker Anterios Inc. in a move that may protect and improve the company's position in aesthetic and therapeutic indications in which the blockbuster wrinkle-reducer and migraine-reliever Botox (onabotulinumtoxinA) is approved.